Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Stefan H. Hohnloser, Ziad Hijazi, Laine Thomas, John H. Alexander, John Amerena, Michael Hanna, Matyas Keltai, Fernando Lanas, Renato D. Lopes, Jose Lopez-Sendon, Christopher B. Granger, Lars Wallentin

Research output: Contribution to journalArticle

359 Citations (Scopus)

Abstract

AimsAtrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We evaluated these outcomes in relation to renal function.Methods and resultsBaseline glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations as well as cystatin C measurements. According to baseline Cockcroft-Gault, there were 7518 patients (42) with an estimated GFR (eGFR) of >80 mL/min, 7587 (42) between >50 and 80 mL/min, and 3017 (15) with an eGFR of ≤50 mL/min. The rate of cardiovascular events and bleeding was higher at impaired renal function (≤80 mL/min). Apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality irrespective of renal function. These results were consistent, regardless of methods for GFR estimation. Apixaban was associated with less major bleeding events across all ranges of eGFRs. The relative risk reduction in major bleeding was greater in patients with an eGFR of ≤50 mL/min using Cockcroft-Gault hazard ratio (HR) 0.50 [95 confidence interval (CI) 0.38-0.66], interaction P = 0.005 or CKD-EPI equations [HR 0.48 (95% CI 0.37-0.64), interaction P = 0.003].ConclusionIn patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban.

Original languageEnglish
Pages (from-to)2821-2830
Number of pages10
JournalEuropean heart journal
Volume33
Issue number22
DOIs
Publication statusPublished - Nov 2012

Keywords

  • Anticoagulation
  • Apixaban
  • Atrial fibrillation
  • Bleeding
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial'. Together they form a unique fingerprint.

  • Cite this

    Hohnloser, S. H., Hijazi, Z., Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., Keltai, M., Lanas, F., Lopes, R. D., Lopez-Sendon, J., Granger, C. B., & Wallentin, L. (2012). Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. European heart journal, 33(22), 2821-2830. https://doi.org/10.1093/eurheartj/ehs274